Diacylglycerol kinase (DGKA) regulates the effect of the epilepsy and bipolar disorder treatment valproic acid inDictyostelium discoideum
Open Access
- 21 August 2018
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 11 (9) , dmm035600
Abstract
Valproic acid (VPA) provides a common treatment for both epilepsy and bipolar disorder; however, common cellular mechanisms relating to both disorders have yet to be proposed. Here, we explore the possibility of a diacylglycerol kinase (DGK) playing a role in regulating the effect of VPA relating to the treatment of both disorders, using the biomedical model Dictyostelium discoideum. DGK enzymes provide the first step in the phosphoinositide recycling pathway, implicated in seizure activity. They also regulate levels of diacylglycerol (DAG), thereby regulating the protein kinase C (PKC) activity that is linked to bipolar disorder-related signalling. Here, we show that ablation of the single Dictyostelium dgkA gene results in reduced sensitivity to the acute effects of VPA on cell behaviour. Loss of dgkA also provides reduced sensitivity to VPA in extended exposure during development. To differentiate a potential role for this DGKA-dependent mechanism in epilepsy and bipolar disorder treatment, we further show that the dgkA null mutant is resistant to the developmental effects of a range of structurally distinct branched medium-chain fatty acids with seizure control activity and to the bipolar disorder treatment lithium. Finally, we show that VPA, lithium and novel epilepsy treatments function through DAG regulation, and the presence of DGKA is necessary for compound-specific increases in DAG levels following treatment. Thus, these experiments suggest that, in Dictyostelium, loss of DGKA attenuates a common cellular effect of VPA relating to both epilepsy and bipolar disorder treatments, and that a range of new compounds with this effect should be investigated as alternative therapeutic agents. This article has an associated First Person interview with the first author of the paper.Keywords
Funding Information
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/L001500/1)
This publication has 78 references indexed in Scilit:
- Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in ratsNeuropharmacology, 2011
- DGK1-encoded Diacylglycerol Kinase Activity Is Required for Phospholipid Synthesis during Growth Resumption from Stationary Phase in Saccharomyces cerevisiaeJournal of Biological Chemistry, 2011
- Increased gene expression of diacylglycerol kinase eta in bipolar disorderInternational Journal of Neuropsychopharmacology, 2010
- Diacylglycerol kinases as sources of phosphatidic acidBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- Dramatic Differences in the Roles in Lipid Metabolism of Two Isoforms of Diacylglycerol KinaseBiochemistry, 2008
- An Unconventional Diacylglycerol Kinase That Regulates Phospholipid Synthesis and Nuclear Membrane GrowthJournal of Biological Chemistry, 2008
- Characterization of the Yeast DGK1-encoded CTP-dependent Diacylglycerol KinaseJournal of Biological Chemistry, 2008
- Attenuation of Phospholipid Signaling Provides a Novel Mechanism for the Action of Valproic AcidEukaryotic Cell, 2007
- A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorderMolecular Psychiatry, 2007
- Disruption of Diacylglycerol Kinase Delta (DGKD) Associated with Seizures in Humans and MiceThe American Journal of Human Genetics, 2007